These findings suggest a multifactorial process through which ARID1A mutations increase tumor proliferation and metastasis, and decrease the sensitivity of ARID1A/EGFR‐comutated NSCLC to EGFR TKI therapy. The gene discussed is ARID1A; the disease is neoplasm.